

Vivian D Hope

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/340989/publications.pdf>

Version: 2024-02-01

128
papers

4,982
citations

94433

37
h-index

106344

65
g-index

132
all docs

132
docs citations

132
times ranked

4313
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. <i>Addiction</i> , 2011, 106, 1978-1988.	3.3	271
2	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. <i>Addiction</i> , 2018, 113, 545-563.	3.3	242
3	Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. <i>International Journal of Drug Policy</i> , 2014, 25, 34-52.	3.3	238
4	Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. <i>PLoS ONE</i> , 2014, 9, e103345.	2.5	184
5	Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. <i>Epidemiology and Infection</i> , 2014, 142, 270-286.	2.1	161
6	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. <i>The Cochrane Library</i> , 2017, 2017, CD012021.	2.8	158
7	Sexualised drug use in the United Kingdom (UK): A review of the literature. <i>International Journal of Drug Policy</i> , 2018, 55, 131-148.	3.3	149
8	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1397-1409.	9.1	147
9	Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2008, 15, 250-254.	2.0	102
10	Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Public Health</i> , The, 2021, 6, e309-e323.	10.0	99
11	Frequency, factors and costs associated with injection site infections: Findings from a national multi-site survey of injecting drug users in England. <i>BMC Infectious Diseases</i> , 2008, 8, 120.	2.9	97
12	HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. <i>BMJ Open</i> , 2012, 2, e001465.	1.9	88
13	Psychosocial and sexual characteristics associated with sexualised drug use and chemsex among men who have sex with men (MSM) in the UK. <i>Sexually Transmitted Infections</i> , 2019, 95, 342-350.	1.9	88
14	Frequency of health care utilization by adults who use illicit drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2020, 115, 1011-1023.	3.3	88
15	Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators. <i>Journal of Epidemiology and Community Health</i> , 2004, 58, 766-771.	3.7	86
16	Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. <i>Journal of Viral Hepatitis</i> , 2007, 14, 645-652.	2.0	86
17	<sc>HCV</sc> treatment rates and sustained viral response among people who inject drugs in seven <sc>UK</sc> sites: real world results and modelling of treatment impact. <i>Journal of Viral Hepatitis</i> , 2015, 22, 399-408.	2.0	86
18	Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. <i>Journal of Viral Hepatitis</i> , 2011, 18, 262-270.	2.0	81

#	ARTICLE	IF	CITATIONS
19	Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. <i>BMJ Open</i> , 2013, 3, e003207.	1.9	81
20	Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. <i>European Journal of Public Health</i> , 2012, 22, 187-192.	0.3	79
21	Identifying a typology of men who use anabolic androgenic steroids (AAS). <i>International Journal of Drug Policy</i> , 2018, 55, 105-112.	3.3	79
22	Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. <i>BMC Infectious Diseases</i> , 2006, 6, 93.	2.9	70
23	Factors mediating HIV risk among female sex workers in Europe: a systematic review and ecological analysis. <i>BMJ Open</i> , 2013, 3, e002836.	1.9	67
24	An evidence synthesis approach to estimating Hepatitis C Prevalence in England and Wales. <i>Statistical Methods in Medical Research</i> , 2009, 18, 361-379.	1.5	65
25	The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England. <i>International Journal of Drug Policy</i> , 2020, 83, 102851.	3.3	61
26	Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: Do we know enough to promote it?. <i>International Journal of Drug Policy</i> , 2018, 58, 31-36.	3.3	58
27	Capturing crack cocaine use: estimating the prevalence of crack cocaine use in London using capture-recapture with covariates. <i>Addiction</i> , 2005, 100, 1701-1708.	3.3	55
28	Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?. <i>American Journal of Epidemiology</i> , 2009, 170, 352-360.	3.4	50
29	Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming. <i>AIDS and Behavior</i> , 2020, 24, 3056-3070.	2.7	50
30	Opiate Injection-associated Skin, Soft Tissue, and Vascular Infections, England, UK, 1997-2016. <i>Emerging Infectious Diseases</i> , 2017, 23, 1400-1403.	4.3	48
31	Groin injecting in the context of crack cocaine and homelessness: From "risk boundary" to "acceptable risk"? <i>International Journal of Drug Policy</i> , 2006, 17, 164-170.	3.3	45
32	Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. <i>Journal of Public Health</i> , 2009, 31, 374-382.	1.8	44
33	Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2019, 19, 723.	2.9	43
34	A narrative systematic review of sexualised drug use and sexual health outcomes among LGBT people. <i>International Journal of Drug Policy</i> , 2021, 93, 103187.	3.3	42
35	HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. <i>Aids</i> , 2005, 19, 1207-1214.	2.2	41
36	Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. <i>Drug and Alcohol Dependence</i> , 2013, 132, 172-181.	3.2	40

#	ARTICLE	IF	CITATIONS
37	Healthcare seeking and hospital admissions by people who inject drugs in response to symptoms of injection site infections or injuries in three urban areas of England. <i>Epidemiology and Infection</i> , 2015, 143, 120-131.	2.1	40
38	Epidemic of severe <i>Streptococcus pyogenes</i> infections in injecting drug users in the UK, 2003–2004. <i>Clinical Microbiology and Infection</i> , 2008, 14, 1002-1009.	6.0	38
39	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
40	Infections with Spore-forming Bacteria in Persons Who Inject Drugs, 2000–2009. <i>Emerging Infectious Diseases</i> , 2013, 19, 29-34.	4.3	37
41	Ongoing outbreak of invasive and non-invasive disease due to group A <i>Streptococcus</i> (GAS) type emm66 among homeless and people who inject drugs in England and Wales, January to December 2016. <i>Eurosurveillance</i> , 2017, 22, .	7.0	37
42	Insights into the rise in HIV infections, 2001 to 2008: a Bayesian synthesis of prevalence evidence. <i>Aids</i> , 2010, 24, 2849-2858.	2.2	36
43	Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection?. <i>Eurosurveillance</i> , 2016, 21, .	7.0	36
44	Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking. <i>Epidemiology and Infection</i> , 2015, 143, 132-140.	2.1	35
45	Estimating prevalence of injecting drug use: a comparison of multiplier and capture-recapture methods in cities in England and Russia. <i>Drug and Alcohol Review</i> , 2006, 25, 131-140.	2.1	34
46	Not in the vein: “missed hits”™, subcutaneous and intramuscular injections and associated harms among people who inject psychoactive drugs in Bristol, United Kingdom. <i>International Journal of Drug Policy</i> , 2016, 28, 83-90.	3.3	34
47	The extent of injection site infection in injecting drug users: findings from a national surveillance study. <i>Epidemiology and Infection</i> , 2010, 138, 1510-1518.	2.1	33
48	Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 331-337.	2.1	33
49	Wound botulism in injectors of drugs: upsurge in cases in England during 2004. <i>Eurosurveillance</i> , 2005, 10, 5-6.	7.0	33
50	Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services. <i>Public Health</i> , 2021, 192, 8-11.	2.9	32
51	The prevalence of injecting drug use in a Russian city: implications for harm reduction and coverage. <i>Addiction</i> , 2004, 99, 1430-1438.	3.3	31
52	The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales. <i>Epidemiology and Infection</i> , 1998, 121, 381-386.	2.1	30
53	Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings—what is required to achieve the WHO’s HCV elimination targets?. <i>Addiction</i> , 2018, 113, 1727-1738.	3.3	30
54	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) — a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	1.9	30

#	ARTICLE	IF	CITATIONS
55	A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. <i>Journal of Viral Hepatitis</i> , 2008, 15, 809-816.	2.0	29
56	Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. <i>Addiction</i> , 2019, 114, 560-570.	3.3	29
57	Injecting-related health harms and overuse of acidifiers among people who inject heroin and crack cocaine in London: a mixed-methods study. <i>Harm Reduction Journal</i> , 2019, 16, 60.	3.2	28
58	Prevalence and severity of abscesses and cellulitis, and their associations with other health outcomes, in a community-based study of people who inject drugs in London, UK. <i>PLoS ONE</i> , 2020, 15, e0235350.	2.5	27
59	Factors associated with recent symptoms of an injection site infection or injury among people who inject drugs in three English cities. <i>International Journal of Drug Policy</i> , 2014, 25, 303-307.	3.3	26
60	Navigating environmental constraints to injection preparation: the use of saliva and other alternatives to sterile water among unstably housed PWID in London. <i>Harm Reduction Journal</i> , 2020, 17, 24.	3.2	26
61	Patterns of injecting and non-injecting drug use by sexual behaviour in people who inject drugs attending services in England, Wales and Northern Ireland, 2013-2016. <i>International Journal of Drug Policy</i> , 2018, 55, 215-221.	3.3	25
62	Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements?. <i>Journal of Viral Hepatitis</i> , 2007, 14, 653-660.	2.0	22
63	Going into the groin: Injection into the femoral vein among people who inject drugs in three urban areas of England. <i>Drug and Alcohol Dependence</i> , 2015, 152, 239-245.	3.2	22
64	Access to needle and syringe programs by people who inject image and performance enhancing drugs. <i>International Journal of Drug Policy</i> , 2016, 31, 199-200.	3.3	22
65	Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales?. <i>Journal of Viral Hepatitis</i> , 2007, 14, 584-591.	2.0	21
66	Mapping HIV/STI behavioural surveillance in Europe. <i>BMC Infectious Diseases</i> , 2010, 10, 290.	2.9	21
67	Sex work amongst people who inject drugs in England, Wales and Northern Ireland: Findings from a National Survey of Health Harms and Behaviours. <i>International Journal of Drug Policy</i> , 2015, 26, 429-433.	3.3	20
68	The extent of and factors associated with self-reported overdose and self-reported receipt of naloxone among people who inject drugs (PWID) in England, Wales and Northern Ireland. <i>International Journal of Drug Policy</i> , 2017, 46, 34-40.	3.3	20
69	Prevent™: rationale for investigating skin and soft tissue infections and AA amyloidosis among people who inject drugs in London. <i>Harm Reduction Journal</i> , 2018, 15, 23.	3.2	20
70	Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. <i>Public Health Research</i> , 2017, 5, 1-118.	1.3	20
71	Respondent driven sampling and community structure in a population of injecting drug users, Bristol, UK. <i>Drug and Alcohol Dependence</i> , 2012, 126, 324-332.	3.2	19
72	Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15. <i>Drug and Alcohol Dependence</i> , 2017, 179, 83-86.	3.2	19

#	ARTICLE	IF	CITATIONS
73	Incidence and treatment costs of severe bacterial infections among people who inject heroin: A cohort study in South London, England. <i>Drug and Alcohol Dependence</i> , 2020, 212, 108057.	3.2	19
74	Factors associated with skin and soft tissue infections among people who inject drugs in the United Kingdom: A comparative examination of data from two surveys. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108080.	3.2	19
75	Modelling the hepatitis B vaccination programme in prisons. <i>Epidemiology and Infection</i> , 2006, 134, 231-242.	2.1	18
76	Monitoring the effectiveness of HIV and STI prevention initiatives in England, Wales, and Northern Ireland: where are we now?. <i>Sexually Transmitted Infections</i> , 2006, 82, 4-10.	1.9	18
77	The experiences of people who inject drugs of skin and soft tissue infections and harm reduction: A qualitative study. <i>International Journal of Drug Policy</i> , 2019, 65, 65-72.	3.3	18
78	A Decade of Spore-Forming Bacterial Infections Among European Injecting Drug Users: Pronounced Regional Variation. <i>American Journal of Public Health</i> , 2012, 102, 122-125.	2.7	17
79	Psychosocial and sexual factors associated with recent sexual health clinic attendance and HIV testing among trans people in the UK. <i>BMJ Sexual and Reproductive Health</i> , 2020, 46, 116-125.	1.7	17
80	Clonal expansion of community-associated meticillin-resistant <i>Staphylococcus aureus</i> (MRSA) in people who inject drugs (PWID): prevalence, risk factors and molecular epidemiology, Bristol, United Kingdom, 2012 to 2017. <i>Eurosurveillance</i> , 2019, 24, .	7.0	17
81	Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. <i>Epidemiology and Infection</i> , 2015, 143, 1398-1407.	2.1	16
82	Sexualised drug use: LGTB communities and beyond. <i>International Journal of Drug Policy</i> , 2018, 55, 128-130.	3.3	16
83	Hepatitis C infection among recent initiates to injecting in England 2000â€“2008: Is a national hepatitis C action plan making a difference?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 55-64.	2.0	15
84	Sustained increase in the sharing of needles and syringes among drug users in England and Wales. <i>Aids</i> , 2002, 16, 2494-2496.	2.2	15
85	Human immunodeficiency virus among people who inject drugs: Is risk increasing in Europe?. <i>Eurosurveillance</i> , 2013, 18, 20648.	7.0	14
86	Modelling HIV in the injecting drug user population and the male homosexual population in a developed country context. <i>Epidemics</i> , 2012, 4, 48-56.	3.0	13
87	Drawing attention to a neglected injectingâ€related harm: a systematic review of AA amyloidosis among people who inject drugs. <i>Addiction</i> , 2018, 113, 1790-1801.	3.3	13
88	Male IDUs who have sex with men in England, Wales and Northern Ireland: are they at greater risk of bloodborne virus infection and harm than those who only have sex with women?. <i>Sexually Transmitted Infections</i> , 2012, 88, 456-461.	1.9	12
89	â€Slammingâ€™ among men who have sex with men accessing general drug services, in response to Schmidt, AJ et al., 2016, Illicit drug use among gay and bisexual men in 44 cities: Findings from the European MSM Internet Survey (EMIS). <i>International Journal of Drug Policy</i> , 2017, 49, 24-25.	3.3	12
90	Wound botulism in injectors of drugs: upsurge in cases in England during 2004. <i>Eurosurveillance</i> , 2005, 10, 172-4.	7.0	12

#	ARTICLE	IF	CITATIONS
91	The characteristics of people who inject drugs in the United Kingdom: changes in age, duration, and incidence of injecting, 1980â€“2019, using evidence from repeated crossâ€“sectional surveys. <i>Addiction</i> , 2022, 117, 2471-2480.	3.3	12
92	Injection into the jugular vein among people who inject drugs in the United Kingdom: Prevalence, associated factors and harms. <i>International Journal of Drug Policy</i> , 2017, 46, 28-33.	3.3	11
93	Associations with drug use and sexualised drug use among women who have sex with women (WSW) in the UK: Findings from the LGBT Sex and Lifestyles Survey. <i>International Journal of Drug Policy</i> , 2019, 74, 292-298.	3.3	11
94	Secondary distribution of injecting equipment obtained from needle and syringe programmes by people injecting image and performance enhancing drugs: England and Wales, 2012-15. <i>Drug and Alcohol Dependence</i> , 2019, 195, 40-44.	3.2	11
95	Service provision and barriers to care for men who have sex with men engaging in chemsex and sexualised drug use in England. <i>International Journal of Drug Policy</i> , 2021, 92, 103090.	3.3	11
96	Generating evidence on the use of Image and performance enhancing drugs in the UK: results from a scoping review and expert consultation by the Anabolic Steroid UK network. <i>Harm Reduction Journal</i> , 2021, 18, 107.	3.2	11
97	Image and performance enhancing drug use among men who have sex with men and women who have sex with women in the UK. <i>International Journal of Drug Policy</i> , 2021, 95, 102933.	3.3	10
98	The impact of directâ€“acting antivirals on hepatitis C viraemia among people who inject drugs in England; realâ€“world data 2011â€“2018. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1452-1463.	2.0	10
99	An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. <i>Addiction</i> , 2016, 111, 1616-1627.	3.3	8
100	Usage of low dead space syringes and association with hepatitis C prevalence amongst people who inject drugs in the UK. <i>Drug and Alcohol Dependence</i> , 2018, 192, 118-124.	3.2	8
101	A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs. <i>Eurosurveillance</i> , 2018, 23, .	7.0	8
102	Modelling the characteristics of the male injecting drug user population in England and Wales. <i>International Journal of Drug Policy</i> , 2005, 16, 176-182.	3.3	7
103	Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services. <i>Epidemiology and Infection</i> , 2012, 140, 1054-1063.	2.1	7
104	Harm reduction interventions should encompass people who inject image and performance enhancing drugs. <i>BMJ, The</i> , 2016, 353, i1889.	6.0	7
105	High prevalence of albuminuria amongst people who inject drugs: A cross-sectional study. <i>Scientific Reports</i> , 2020, 10, 7059.	3.3	7
106	Factors associated with the use of cleaned needles and syringes among people who inject drugs in the UK: Who should we target to minimise the risks?. <i>International Journal of Drug Policy</i> , 2014, 25, 924-927.	3.3	6
107	Human enhancement drugs: Emerging issues and responses. <i>International Journal of Drug Policy</i> , 2021, 95, 103459.	3.3	6
108	Factors associated with hepatitis C and <sc>HIV</sc> testing uptake among men who inject image and performance enhancing drugs. <i>Drug and Alcohol Review</i> , 2021, 40, 586-596.	2.1	5

#	ARTICLE	IF	CITATIONS
109	Prevalence and factors associated with chronic venous insufficiency, leg ulceration and deep vein thrombosis among people who inject drugs in London, UK. <i>Drug and Alcohol Review</i> , 2022, 41, 677-685.	2.1	5
110	The HIV epidemic in injecting drug users. <i>Communicable Disease Report CDR Review</i> , 1997, 7, R128-30.	0.3	5
111	Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: Nearly 40 years on. <i>HIV Medicine</i> , 2022, 23, 978-989.	2.2	5
112	Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise. <i>Drugs: Education, Prevention and Policy</i> , 2023, 30, 461-473.	1.3	5
113	Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?. <i>Eurosurveillance</i> , 2021, 26, .	7.0	4
114	O-08: The impact of 25 years of sero-behavioural surveillance of blood borne viral infections among people who inject drugs in the United Kingdom. <i>Journal of Viral Hepatitis</i> , 2015, 22, 5-5.	2.0	2
115	Spore forming bacteria infections and people who inject drugs: Implications for harm reduction. <i>International Journal of Drug Policy</i> , 2018, 53, 45-54.	3.3	2
116	“Belt and braces approach; added benefit and extra reassurance” a multi-stakeholder examination of the challenges to effective provision of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM) in Northern and Central England. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 736-745.	1.2	2
117	Infections and risk among people who use image and performance enhancing drugs. , 2019, , 85-100.		2
118	Mapping HIV-related behavioural surveillance among injecting drug users in Europe, 2008. <i>Eurosurveillance</i> , 2011, 16, .	7.0	2
119	Systems mapping to understand complexity in the association between image and performance enhancing drugs (IPEDs) and harm. <i>International Journal of Drug Policy</i> , 2022, 107, 103801.	3.3	2
120	A comparison of HIV related advice in genitourinary medicine clinics with different histories.. <i>Sexually Transmitted Infections</i> , 1996, 72, 286-289.	1.9	1
121	Relation between information and advice provision to male GUM clinic attendees and sexual orientation and ethnic group. <i>Sexually Transmitted Infections</i> , 2000, 76, 198-202.	1.9	1
122	Hepatitis B vaccination for people who inject drugs. <i>Lancet, The</i> , 2015, 385, 115-116.	13.7	1
123	The cost-effectiveness of needle and syringe provision in preventing transmission of Hepatitis C virus in people who inject drugs. <i>Journal of Hepatology</i> , 2018, 68, S146-S147.	3.7	1
124	Sexually transmitted infection diagnoses, sexualised drug use and associations with pre-exposure prophylaxis use among men who have sex with men in the UK. <i>International Journal of STD and AIDS</i> , 2020, 31, 254-263.	1.1	1
125	Response to Marsden et al (2020): Mitigation for the impacts on needle and syringe programmes is needed. <i>Addiction</i> , 2021, 116, 206-207.	3.3	1
126	P1284 FACTORS ASSOCIATED WITH RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS IN THE UNITED KINGDOM: NEW FINDINGS USING AN AVIDITY TESTING ALGORITHM. <i>Journal of Hepatology</i> , 2014, 60, S518.	3.7	0

#	ARTICLE	IF	CITATIONS
127	P127: Factors associated with undiagnosed hepatitis C infection among people who inject drugs and missed opportunities for testing in the United Kingdom. <i>Journal of Viral Hepatitis</i> , 2015, 22, 84-85.	2.0	0
128	Epidemiology of Hepatitis C Virus: People Who Inject Drugs and Other Key Populations. , 2021, , 109-149.		0